Related Experiment Video
Updated: Jul 17, 2026
In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Can Glypican-6 Levels Be Used to Determine Right Ventricular Remodeling After Non-ST Segment Elevation Myocardial
Uğur Küçük1, Emir Volina1, Kadir Arslan1
1Department of Cardiology, Canakkale Onsekiz Mart University Faculty of Medicine, Canakkale, Türkiye.
Insights
Glypican-6 (GPC6) predicts right ventricular (RV) remodeling after myocardial infarction. Higher GPC6 levels indicate increased risk, aiding early detection in NSTEMI patients undergoing PCI.
Area of Science:
- Cardiology
- Biomarkers
- Cardiac Remodeling
Background:
- Myocardial infarction (MI) often leads to right ventricular (RV) remodeling.
- Glypican-6 (GPC6) is implicated in cardiac remodeling processes.
- Predictive markers for RV remodeling post-MI are crucial.
Purpose of the Study:
- To investigate Glypican-6 (GPC6) as a predictor of RV remodeling.
- To assess GPC6 levels in patients with non-ST segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI).
Main Methods:
- 164 NSTEMI patients and controls were analyzed.
- Baseline plasma GPC6 levels and echocardiography were compared between RV remodeling and non-RV remodeling groups.
- Echocardiographic RV dimensions were measured at baseline and 6 months post-PCI.
Main Results:
- NSTEMI patients had higher baseline GPC6 levels compared to controls.
- RV remodeling occurred in 30% of NSTEMI patients, with significant RV enlargement after 6 months.
- Elevated GPC6 levels (>15.5 ng/mL) independently predicted RV remodeling with high accuracy (AUC=0.828).
Conclusions:
- Glypican-6 (GPC6) is a significant independent predictor of RV remodeling post-NSTEMI.
- GPC6 shows potential as a biomarker for identifying NSTEMI patients at risk of RV remodeling.
- Close monitoring for RV remodeling is recommended for NSTEMI patients.
Objective:
Myocardial infarction is associated with right ventricular (RV) remodeling. Glypican-6 (GPC6), a member of the membrane proteoglycan family, plays a significant role in cardiac remodeling. This study aims to determine if GPC6 can predict RV remodeling after percutaneous coronary intervention (PCI) in patients with non-ST segment elevation myocardial infarction (NSTEMI).
Methods:
The study enrolled 164 consecutive patients with NSTEMI and controls. It compared baseline plasma GPC6 levels, echocardiography, and laboratory parameters between the RV remodeling and non-RV remodeling groups with NSTEMI. Echocardiographic data were measured at baseline and at six months.
Results:
GPC6 levels were higher in the NSTEMI group 11.06 ng/mL (4.61-18.17) vs. 5.98 ng/mL (3.81-9.83) compared to the control group in the initial phase. RV remodeling, defined as a ≥ 20% increase in RV end-diastolic area (RV EDA), was observed in 23 patients (30%). After six months, RV EDA increased significantly from baseline 18.68 ± 1.20 cm2 vs. 24.91 ± 1.08 cm2, P < 0.001. GPC6 was a significant independent predictor of RV remodeling (hazard ratio [HR]: 1.546, 95% confidence interval [CI]: 1.056-2.245, P < 0.001). Receiver operating characteristic curve (ROC) analyses showed that GPC6 values > 15.5 ng/mL (area under the curve [AUC] = 0.828, sensitivity: 70%, specificity: 74%, P < 0.001) were strong predictors of RV remodeling.
Conclusion:
NSTEMI patients should be closely monitored for RV remodeling. GPC6 appears useful in detecting RV remodeling following NSTEMI in patients undergoing PCI.
Related Concept Videos
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
01:30Acute Coronary Syndrome III: Diagnostic Studies